Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 291

1.

PARP inhibitors: its role in treatment of cancer.

Chen A.

Chin J Cancer. 2011 Jul;30(7):463-71. doi: 10.5732/cjc.011.10111. Review.

2.

[PARP inhibitors--theoretical basis and clinical application].

Dębska S, Kubicka J, Czyżykowski R, Habib M, Potemski P.

Postepy Hig Med Dosw (Online). 2012 May 30;66:311-21. Review. Polish.

3.

The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.

Chionh F, Mitchell G, Lindeman GJ, Friedlander M, Scott CL.

Asia Pac J Clin Oncol. 2011 Sep;7(3):197-211. doi: 10.1111/j.1743-7563.2011.01430.x. Review.

PMID:
21884432
4.

Advances in PARP inhibitors for the treatment of breast cancer.

Dizdar O, Arslan C, Altundag K.

Expert Opin Pharmacother. 2015;16(18):2751-8. doi: 10.1517/14656566.2015.1100168. Epub 2015 Oct 20. Review.

PMID:
26485111
5.

The potential of PARP inhibitors in genetic breast and ovarian cancers.

Drew Y, Calvert H.

Ann N Y Acad Sci. 2008 Sep;1138:136-45. doi: 10.1196/annals.1414.020.

PMID:
18837894
6.

PARP inhibitors in breast cancer: BRCA and beyond.

Rios J, Puhalla S.

Oncology (Williston Park). 2011 Oct;25(11):1014-25. Review.

7.

[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].

Schreiber V, Illuzzi G, Héberlé E, Dantzer F.

Bull Cancer. 2015 Oct;102(10):863-73. doi: 10.1016/j.bulcan.2015.07.012. Epub 2015 Sep 15. Review. French.

PMID:
26384693
8.

Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?

Plummer R.

Breast Cancer Res. 2011 Aug 16;13(4):218. doi: 10.1186/bcr2877. Review.

9.

[Research progresses of the PARP inhibitors for the treatment of cancer].

He YJ, Liu RH, Ning CQ, Yu NF.

Yao Xue Xue Bao. 2013 May;48(5):655-60. Review. Chinese.

PMID:
23888686
10.

[PARP inhibitors and breast cancer: update and perspectives].

Gonçalves A.

Bull Cancer. 2012 Apr 1;99(4):441-51. doi: 10.1684/bdc.2012.1553. Review. French.

11.

Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.

Heerma van Voss MR, Brilliant JD, Vesuna F, Bol GM, van der Wall E, van Diest PJ, Raman V.

Med Oncol. 2017 Mar;34(3):33. doi: 10.1007/s12032-017-0889-2. Epub 2017 Jan 30.

12.

Inducing synthetic lethality using PARP inhibitors.

Boss DS, Beijnen JH, Schellens JH.

Curr Clin Pharmacol. 2010 Aug;5(3):192-5. Review.

PMID:
20406170
13.

PARP inhibitors in ovarian cancer: current status and future promise.

Liu JF, Konstantinopoulos PA, Matulonis UA.

Gynecol Oncol. 2014 May;133(2):362-9. doi: 10.1016/j.ygyno.2014.02.039. Epub 2014 Mar 4. Review.

PMID:
24607283
14.

[Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].

Kluzek K, Białkowska A, Koczorowska A, Zdzienicka MZ.

Postepy Hig Med Dosw (Online). 2012 Jun 15;66:372-84. Review. Polish.

15.

Poly(ADP-ribose) polymerase inhibitors as cancer therapy.

Hilton JF, Hadfield MJ, Tran MT, Shapiro GI.

Front Biosci (Landmark Ed). 2013 Jun 1;18:1392-406. Review.

PMID:
23747892
16.

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A.

Lancet Oncol. 2011 Sep;12(9):852-61. doi: 10.1016/S1470-2045(11)70214-5. Epub 2011 Aug 19.

PMID:
21862407
17.

[PARP inhibitors: new therapeutic agents in breast and ovarian cancer].

Mercier-Vogel L, Bodmer A, Castiglione M.

Rev Med Suisse. 2011 May 25;7(296):1137-40. French.

PMID:
21721203
18.

Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.

Kyle S, Thomas HD, Mitchell J, Curtin NJ.

Br J Radiol. 2008 Oct;81 Spec No 1:S6-11. doi: 10.1259/bjr/99111297.

PMID:
18820000
19.

Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.

Wang D, Li C, Zhang Y, Wang M, Jiang N, Xiang L, Li T, Roberts TM, Zhao JJ, Cheng H, Liu P.

Gynecol Oncol. 2016 Sep;142(3):548-56. doi: 10.1016/j.ygyno.2016.07.092. Epub 2016 Jul 15.

20.

Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer.

Comen EA, Robson M.

Oncology (Williston Park). 2010 Jan;24(1):55-62. Review.

Supplemental Content

Support Center